Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observer-Blinded Phase 3 Study to Evaluate the Safety and Immunogenicity of a Single Booster of the NVX-CoV2373 Vaccine in Adults Previously Vaccinated With the BBIBP-CorV Vaccine

Next Previous
Search
Trial Profile

An Observer-Blinded Phase 3 Study to Evaluate the Safety and Immunogenicity of a Single Booster of the NVX-CoV2373 Vaccine in Adults Previously Vaccinated With the BBIBP-CorV Vaccine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-19 vaccine adjuvanted Novavax (Primary) ; BBIBP CorV; Matrix M
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 04 Apr 2023 According to Novavax media release, data from this study will be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases.
    • 27 Mar 2023 Status changed from recruiting to completed.
    • 25 Mar 2022 According to Novavax media release, Novavax is participating in this trial, participants from this trial will be followed for six months, with full results expected during the fourth quarter of 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top